Factors linked to death in Streptococcal anginosus bloodstream infection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study reviews adults hospitalized between January 1, 2019 and December 31, 2024 at participating centers who had at least one positive blood culture for Streptococcus anginosus, S. constellatus, or S. intermedius. Investigators will extract clinical, microbiological, comorbidity, and treatment data from hospital records and analyze which patient characteristics, infection sources, or management factors are associated with in-hospital mortality. No experimental treatments are given; the work is a retrospective chart-based analysis and excludes patients who refuse participation. The aim is to identify risk factors that could guide earlier recognition and more targeted care for high-risk patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Major subject (≥18 years old)
* Hospitalized between January 1, 2019, and December 31, 2024, in one of the participating centers
* Having presented during the study period at least one positive blood culture for Streptococcus anginosus, Streptococcus constellatus, or Streptococcus intermedius in a laboratory at a participating center

Exclusion Criteria:

* Refusal to participate in the study

Where it's running

• Centre de référence des maladies vectorielles à tiques, CNR Borrelia - CHU de Strasbourg - France
  Strasbourg, France Recruiting

Study contacts

• Study coordinator: Victor GERBER, MD
• Email: victor.gerber@chru-strasbourg.fr
• Phone: 33 3 68 85 37 97

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Safety and immune response testing of a 4-component Strep A vaccine with Alum or AS37 in healthy 18–25-year-olds

  This will test three dose levels of two new Strep A vaccine formulations (one with Alum, one with AS37) in healthy 18–25-year-olds to see if they are safe and trigger immune responses.

  Recruiting at 2 sites Phase 1 GlaxoSmithKline · Botany, New South Wales and 1 other locations · NCT07085702

• Investigating markers in children with sudden-onset neuropsychiatric symptoms

  This study is testing if certain biological markers in children with sudden neuropsychiatric symptoms can help us understand Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) better.

  Recruiting Stanford University · Palo Alto, California · NCT02889016

• See if SalivIQ Strep A detects strep throat in kids and adults

  This study tests whether the SalivIQ Strep A test can correctly identify Group A Streptococcus in people with suspected strep throat using saliva and throat swabs.

  Recruiting at 3 sites SalivIQ Diagnostics, Inc. · Baton Rouge, Louisiana and 2 other locations · NCT07891728

• VAX-A1: a first-in-human test for safety and immune response in healthy adults

  This phase 1 trial tests a new vaccine called VAX-A1 in healthy adults 18-40 to see if it is safe, tolerable, and can provoke an immune response.

  Recruiting Phase 1 Vaxcyte, Inc. · Adelaide, South Australia · NCT07616934

• Understanding Group A Streptococcus in Children

  This study is trying to understand the differences in Group A strep bacteria between kids who are sick and those who carry the bacteria without symptoms, to help improve treatment options.

  Recruiting University of Wisconsin, Madison · Madison, Wisconsin · NCT01558804

• Evaluating patterns in neurodevelopmental disorders

  This study is trying to find common signs and causes of neurodevelopmental disorders like Autism and Down Syndrome to help with earlier diagnosis and better outcomes for those affected.

  Recruiting Rossignol Medical Center · Phoenix, Arizona · NCT06213090

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.